374794-77-1

Basic information

• Product Name: N-Boc-3-Methylpiperidin-4-one
• Synonyms: N-Boc-3-Methylpiperidin-4-one;4-Methyl-3-oxo-1-piperidinecarboxylic acid tert-butyl ester;4-Methyl-3-oxo-piperidine-1-carboxylic acid tert-butyl ester;tert-butyl 4-methyl-3-oxopiperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-methyl-3-oxo-, 1,1-dimethylethyl ester
• CAS NO: 374794-77-1
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.27346
• Mol File: 374794-77-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 298.8±33.0 °C(Predicted)
• Appearance: /
• Density: 1.060
• PKA: -1.67±0.40(Predicted)
• CAS DataBase Reference: N-Boc-3-Methylpiperidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-3-Methylpiperidin-4-one(374794-77-1)
• EPA Substance Registry System: N-Boc-3-Methylpiperidin-4-one(374794-77-1)

Safety Data

• Hazardous Substances Data: 374794-77-1(Hazardous Substances Data)

Usage

General Description

N-Boc-3-Methylpiperidin-4-one is a chemical compound primarily used in the pharmaceutical industry. It plays a crucial role in drug synthesis, specifically as a component of blocks or precursors for the manufacturing of various drugs. The compound, also referred to by its IUPAC name tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate, belongs to the organic class of compounds known as piperidines. It features a piperidin-4-one backbone, with a methyl group and a tert-butyl group attached. The molecule is distinguished by its distinct polar as well as nonpolar sections, which confer it versatile chemical reactivity. It's typically prepared through synthetic means, rather than extracted from natural sources.

Upstream product

• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1408076-42-5 4-methylpiperidin-3-one hydrochloride 
• 1121-19-3 4-methylpyridin-3-ol 
• 175406-94-7 1-benzyl-3-oxopiperidine-4-carboxylic acid methyl ester 
• 32018-96-5 1-benzyl-4-methyl-piperidin-3-one 
• 1188264-78-9 trans-(RS)-1,1-dimethylethyl 3-hydroxy-4-methylpiperidinecarboxylate 

Downstream Products

• 374794-78-2 (RS)-3,3-Difluoro-4-methylpiperidine Hydrochloride 
• 1260590-51-9 N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-D]pyrimidin-4-amine hydrochloride 
• 1207853-61-9 (3R,4R)-3-amino-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 1312762-43-8 (3R,4R)-4-methyl-3-(methyl-((R)-1-phenylethyl)amino)piperidine-1-carboxylic acid tert-butyl ester 
• 1312762-44-9 (3R,4R)-3-methylamino-4-methylpiperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

CYCLIC COMPOUNDS AND METHODS OF USING SAME

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.

A method for synthesis of piperidine derivatives (by machine translation)

The invention discloses a method for synthesis of piperidine derivatives. The piperidine derivatives of the formula (I) of the tartrate: Wherein R1 Is an amino protecting group, R2 Is phenyl or alkyl substituted phenyl, R3 Is C1 - C6 alkyl; by the piperidine derivative having the structural formula (II) with a compound L - tartaric acid reaction, then the obtained through separation, In the having piperidine 3 bit reference into the S on amino-substituted radical, can significantly improve the for tartaric acid from L - In the separate The effect of the. The method can be used for the synthesis of pharmaceutical Tofacitinib, in order to improve the yield of drug Tofacitinib. (by machine translation)

Cyclohexyl derivatives and their use as therapeutic agents

The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R?17, R18, R19, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.